Biohaven Ltd. (BHVN)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Biohaven Ltd. (BHVN)
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Key Insights
Critical company metrics and information
Share Price
$43.35Market Cap
$4.38 BillionTotal Outstanding Shares
101.12 Million SharesTotal Employees
239Dividend
No dividendIPO Date
September 23, 2022SIC Description
Pharmaceutical PreparationsHomepage
https://www.biohavenpharma.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $80.38 Million |
| Net Cash Flow From Investing Activities | $-93.40 Million |
| Net Cash Flow From Operating Activities | $-141.28 Million |
| Net Cash Flow From Financing Activities, Continuing | $80.38 Million |
| Net Cash Flow From Operating Activities, Continuing | $-141.28 Million |
| Exchange Gains/Losses | $0.00 |
| Net Cash Flow From Investing Activities, Continuing | $-93.40 Million |
| Net Cash Flow, Continuing | $-154.30 Million |
| Net Cash Flow | $-154.30 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Parent | $-160.30 Million |
| Basic Earnings Per Share | $-1.70 |
| Operating Income/Loss | $-178.17 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-160.30 Million |
| Basic Average Shares | $94.37 Million |
| Income Tax Expense/Benefit | $-59,000.00 |
| Diluted Earnings Per Share | $-1.70 |
| Revenues | $0.00 |
| Income/Loss From Continuing Operations After Tax | $-160.30 Million |
| Costs And Expenses | $178.17 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Research and Development | $157.61 Million |
| Income/Loss From Continuing Operations Before Tax | $-160.36 Million |
| Diluted Average Shares | $94.37 Million |
| Nonoperating Income/Loss | $17.80 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Net Income/Loss | $-160.30 Million |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Intangible Assets | $18.40 Million |
| Fixed Assets | $18.28 Million |
| Liabilities And Equity | $510.52 Million |
| Equity Attributable To Parent | $316.01 Million |
| Current Liabilities | $152.29 Million |
| Prepaid Expenses | $55.17 Million |
| Other Current Liabilities | $116.67 Million |
| Accounts Payable | $19.74 Million |
| Noncurrent Assets | $70.02 Million |
| Noncurrent Liabilities | $42.22 Million |
| Other Non-current Assets | $33.35 Million |
| Equity | $316.01 Million |
| Assets | $510.52 Million |
| Other Current Assets | $385.33 Million |
| Current Assets | $440.50 Million |
| Wages | $15.88 Million |
| Liabilities | $194.52 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.